GlassScriptPhysician profile
Marianne Bowman
NPI 1790268977
$3,406.20
in general payments reported to CMS, 2019-2025
25 companies · $574 in 2025
The $574 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $349 · 2022: $761 · 2023: $1,020 · 2024: $703 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,296.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $714.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $675.09 | 2021-2025 | |
| Lilly USA, LLC | $346.02 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $293.57 | 2021-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $244.78 | 2022-2023 | Xarelto |
| Pfizer INC. | $163.24 | 2022-2025 | |
| Amgen INC. | $150.40 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $96.68 | 2021-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $87.93 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $80.56 | 2023-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $79.96 | 2024-2025 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $79.46 | 2021-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.58 | 2021-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $42.24 | 2022 | |
| Sumitomo Pharma America, INC. | $39.75 | 2023-2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $37.96 | 2021 | |
| Sunovion Pharmaceuticals INC. | $36.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.11 | 2023-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $21.72 | 2022 | |
| Horizon Therapeutics Plc | $21.41 | 2021 | |
| Corium, LLC | $19.53 | 2022 | |
| Merck Sharp & Dohme LLC | $17.33 | 2021 | |
| Mylan Specialty L.P. | $15.65 | 2023 | Yupelri |
| Sanofi-Aventis U.S. LLC | $14.90 | 2022 | |
| Currax Pharmaceuticals LLC | $14.30 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marianne Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.